Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
Isotopes that exhibit radioactivity and undergo radioactive decay. (From Grant & Hackh's Chemical Dictionary, 5th ed & McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Rhenium. A metal, atomic number 75, atomic weight 186.2, symbol Re. (Dorland, 28th ed)
Lutetium. An element of the rare earth family of metals. It has the atomic symbol Lu, atomic number 71, and atomic weight 175.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
Antibodies produced by a single clone of cells.
A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic.
The measurement of radiation by photography, as in x-ray film and film badge, by Geiger-Mueller tube, and by SCINTILLATION COUNTING.
Positively charged particles composed of two protons and two NEUTRONS, i.e. equivalent to HELIUM nuclei, which are emitted during disintegration of heavy ISOTOPES. Alpha rays have very strong ionizing power, but weak penetrability.
Unstable isotopes of indium that decay or disintegrate emitting radiation. In atoms with atomic weights 106-112, 113m, 114, and 116-124 are radioactive indium isotopes.
A metallic element that has the atomic symbol Bi, atomic number 83 and atomic weight 208.98.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
The total amount of radiation absorbed by tissues as a result of radiotherapy.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
Unstable isotopes of lead that decay or disintegrate emitting radiation. Pb atoms with atomic weights 194-203, 205, and 209-214 are radioactive lead isotopes.
Astatine. A radioactive halogen with the atomic symbol At, atomic number 85, and atomic weight 210. Its isotopes range in mass number from 200 to 219 and all have an extremely short half-life. Astatine may be of use in the treatment of hyperthyroidism.
A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera.
Actinium. A trivalent radioactive element and the prototypical member of the actinide family. It has the atomic symbol Ac, atomic number 89, and atomic weight 227.0278. Its principal isotope is 227 and decays primarily by beta-emission.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A 60-kDa extracellular protein of Streptomyces avidinii with four high-affinity biotin binding sites. Unlike AVIDIN, streptavidin has a near neutral isoelectric point and is free of carbohydrate side chains.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.
Compounds that are used in medicine as sources of radiation for radiotherapy and for diagnostic purposes. They have numerous uses in research and industry. (Martindale, The Extra Pharmacopoeia, 30th ed, p1161)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Semisynthetic conjugates of various toxic molecules, including RADIOACTIVE ISOTOPES and bacterial or plant toxins, with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; and ANTIGENS. The antitumor or antiviral immune substance carries the toxin to the tumor or infected cell where the toxin exerts its poisonous effect.
Ytterbium. An element of the rare earth family of metals. It has the atomic symbol Yb, atomic number 70, and atomic weight 173. Ytterbium has been used in lasers and as a portable x-ray source.
Unstable isotopes of copper that decay or disintegrate emitting radiation. Cu atoms with atomic weights 58-62, 64, and 66-68 are radioactive copper isotopes.
The relationship between the dose of administered radiation and the response of the organism or tissue to the radiation.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Transplantation between animals of different species.
A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Neptunium. A radioactive element of the actinide metals family. It has the atomic symbol Np, atomic number 93, and atomic weight 237.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
The amount of radiation energy that is deposited in a unit mass of material, such as tissues of plants or animal. In RADIOTHERAPY, radiation dosage is expressed in gray units (Gy). In RADIOLOGIC HEALTH, the dosage is expressed by the product of absorbed dose (Gy) and quality factor (a function of linear energy transfer), and is called radiation dose equivalent in sievert units (Sv).
Techniques for labeling a substance with a stable or radioactive isotope. It is not used for articles involving labeled substances unless the methods of labeling are substantively discussed. Tracers that may be labeled include chemical substances, cells, or microorganisms.
A water-soluble, enzyme co-factor present in minute amounts in every living cell. It occurs mainly bound to proteins or polypeptides and is abundant in liver, kidney, pancreas, yeast, and milk.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
High energy POSITRONS or ELECTRONS ejected from a disintegrating atomic nucleus.
A class of compounds of the type R-M, where a C atom is joined directly to any other element except H, C, N, O, F, Cl, Br, I, or At. (Grant & Hackh's Chemical Dictionary, 5th ed)
A specific protein in egg albumin that interacts with BIOTIN to render it unavailable to mammals, thereby producing biotin deficiency.
Ring compounds having atoms other than carbon in their nuclei. (Grant & Hackh's Chemical Dictionary, 5th ed)
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
Antibodies obtained from a single clone of cells grown in mice or rats.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Tumors or cancer of the COLON.
Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.
Measurement of radioactivity in the entire human body.
A specialty field of radiology concerned with diagnostic, therapeutic, and investigative use of radioactive compounds in a pharmaceutical form.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Separation systems containing a relatively long-lived parent radionuclide which produces a short-lived daughter in its decay scheme. The daughter can be periodically extracted (milked) by means of an appropriate eluting agent.
An inhibitor of nucleotide metabolism.
The ratio of radiation dosages required to produce identical change based on a formula comparing other types of radiation with that of gamma or roentgen rays.
A cell line derived from cultured tumor cells.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Tumors or cancer of the PERITONEUM.
Presentation of pertinent data by one with special skill or knowledge representing mastery of a particular subject.
A general term for various neoplastic diseases of the lymphoid tissue.
Computer-assisted mathematical calculations of beam angles, intensities of radiation, and duration of irradiation in radiotherapy.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
The total amount of a chemical, metal or radioactive substance present at any time after absorption in the body of man or animal.
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
A method of computed tomography that uses radionuclides which emit a single photon of a given energy. The camera is rotated 180 or 360 degrees around the patient to capture images at multiple positions along the arc. The computer is then used to reconstruct the transaxial, sagittal, and coronal images from the 3-dimensional distribution of radionuclides in the organ. The advantages of SPECT are that it can be used to observe biochemical and physiological processes as well as size and volume of the organ. The disadvantage is that, unlike positron-emission tomography where the positron-electron annihilation results in the emission of 2 photons at 180 degrees from each other, SPECT requires physical collimation to line up the photons, which results in the loss of many available photons and hence degrades the image.
Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS.
Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A group of dominantly and independently inherited antigens associated with the ABO blood factors. They are glycolipids present in plasma and secretions that may adhere to the erythrocytes. The phenotype Le(b) is the result of the interaction of the Le gene Le(a) with the genes for the ABO blood groups.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Rate of energy dissipation along the path of charged particles. In radiobiology and health physics, exposure is measured in kiloelectron volts per micrometer of tissue (keV/micrometer T).
High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Samarium. An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.
Small antigenic determinants capable of eliciting an immune response only when coupled to a carrier. Haptens bind to antibodies but by themselves cannot elicit an antibody response.
Davies, A J (28 May 2007). "Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab". Oncogene. ... Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. It was combined with ...
Alternatively, in radioimmunotherapy a radioactive dose localizes a target cell line, delivering lethal chemical doses. More ... can affect T cell functions directly and indirectly via cells such as Treg cells. CD8 cells can be suppressed by B cells ... Monoclonal antibodies can target tumor cells or abnormal cells in the body that are recognized as body cells, but are ... Tumor vasculature helps tumors preferentially recruit other immune cells over T cells, in part through endothelial cell (EC)- ...
"EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)" ( ... to kill it and some nearby cells. In addition, the antibody itself may trigger cell death via antibody-dependent cell-mediated ... The antibody binds to the CD20 antigen found on the surface of normal and malignant B cells (but not B cell precursors), ... Together, these actions eliminate B cells from the body, allowing a new population of healthy B cells to develop from lymphoid ...
Though many α-emitters exist, useful isotopes would have a sufficient energy to cause damage to cancer cells, and a half-life ... Larson, Steven M.; Carrasquillo, Jorge A.; Cheung, Nai-Kong V.; Press, Oliver W. (22 May 2015). "Radioimmunotherapy of human ... It has the potential to provide highly targeted treatment, especially to microscopic tumour cells. Targets include leukemias, ... Seidl, Christof (April 2014). "Radioimmunotherapy with α-particle-emitting radionuclides". Immunotherapy. 6 (4): 431-458. doi: ...
CD8 cells, often referred to as "killer" T cells, are one of the major cells of the adaptive immune response, and are capable ... as a radioimmunotherapy agent, and in combination with chemotherapy. Establishment of the autologous typing system as the ... Identified the first cell surface antigens distinguishing cells of different lineages, introducing the concept of cell surface ... expressed on over 90 percent of clear cells renal cell carcinomas (RCC, kidney cancer), and is in phase III clinical trials as ...
188Re (Rhenium) as Rhenium-SCT for treatment of Non-Melanoma Skin Cancer (basal cell carcinoma or squamous cell carcinoma) ... and radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin) & 131I tositumomab (Bexxar) therapy of low-grade non-Hodgkin's ... and white blood cell studies for infection. Examples of uncommon but valuable procedures are octreotide (pentetreotide) or ... heat-damaged red blood cell imaging for identifying ectopic splenic tissue, and gastric mucosa imaging for Meckel's ...
There are newer[when?] variations on monoclonal antibodies combined with radioactive molecules known as radioimmunotherapy (RIT ... By binding to CD19-expressing cancer cells and normal B cells, the medicine starts T‑cell activation and secretion of ... MCL cell types can aid in prognosis in a subjective way. Blastic is a larger cell type. Diffuse is spread through the node. ... The recipient's T cells, a type of white blood cell, are collected and genetically modified to include a new gene that ...
This capability does not seem to be dependent on the stage of the cell cycle or the level of oxygenation of the cancer cell.[ ... Seidl, C (2014). "Radioimmunotherapy with α-particle-emitting radionuclides". Immunotherapy. 6 (4): 431-58. doi:10.2217/imt. ... Because the alpha-emitting atoms diffuse only a few millimeters in tissue, the DaRT eradicates the tumor cells and spares the ... Alpha radiation possesses a potent cell-killing capability because it has a high linear energy transfer (LET) which translates ...
"Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell ... July 2005). "Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized ... Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells. Elevated CD22 and other B-cell receptor (BCR) ... Other SLE therapies destroy B-cells which compromises the immune system.) Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T ...
October 2003). "Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer ... in patients with head and neck squamous cell carcinoma". Clinical Cancer Research. 9 (10 Pt 2): 3961S-72S. PMID 14506195. " ...
... uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell.[1] In cancer ... Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185-208. *^ Quang TS, Brady LW. Radioimmunotherapy as a novel treatment ... RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells. ... FIbritumomab Tiuxetan (Zevalin™) Radioimmunotherapy of Non-Hodgkin's Lymphoma *^ Rao AV, Akabani G, Rizzieri DA. ...
These include: ofatumumab, a monoclonal antibody that is stronger than rituximab in binding to CD20; two radioimmunotherapy ... The neoplastic cells in DLBCL are derived primarily from either germinal center B-cells (i.e. GBC) or activated B-cells (i.e. ... The sites may also contain poorly differentiated cells; but rarely have T-cells, eosinophils, or plasma cells. The lesion's ... LT in that its neoplastic B-cells are germinal center B-cells rather than activated B-cells (see Pathophysiology section) that ...
Sharkey, Robert M.; Goldenberg, David M. (2006-01-01). "Advances in Radioimmunotherapy in the Age of Molecular Engineering and ... Köhler, G.; Milstein, C. (August 1975). "Continuous cultures of fused cells secreting antibody of predefined specificity". ... Immunology and Cell Biology. 68 ( Pt 6) (6): 367-376. doi:10.1038/icb.1990.50. ISSN 0818-9641. PMID 1711007. S2CID 9138513. ... "Pretargeted radioimmunotherapy of cancer: progress step by step". Journal of Nuclear Medicine. 44 (3): 400-411. ISSN 0161-5505 ...
... after being absorbed by the cell, causing harm to the cell's mitochondria and eventually leading to cell death. Further ... Wu C, Brechbiel MW, Kozak RW, Gansow OA (1994). "Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and ... It has been established that cationic macromolecules in general destabilize the cell membrane, which can lead to lysis and cell ... cell breakdown (LDH assay), and nucleus morphology (DAPI staining). However, in other cell lines, the MTT assay and several ...
Targeting double-stranded breaks increases the probability that cells will undergo cell death. Cancer cells are generally less ... These medications were the first agents of what is known as radioimmunotherapy, and they were approved for the treatment of ... Fractionation allows normal cells time to recover, while tumor cells are generally less efficient in repair between fractions. ... Single-strand DNA damage is then passed on through cell division; damage to the cancer cells' DNA accumulates, causing them to ...
Adoptive cell transfer refers to the application of pre-stimulated, modified T cells or dendritic cells and is presently used ... Radioimmunotherapy of metastatic melanoma is currently under investigation. Radiotherapy has a role in the palliation of ... When the cell divides, these mutations are propagated to new generations of cells. If the mutations occur in protooncogenes or ... The first treatment involves adoptive cell therapy (ACT) using TILs immune cells (tumor-infiltrating lymphocytes) isolated from ...
... seems to function by inhibiting the FAK/src/AKT pathway and inducing apoptosis in endothelial cells. Preclinical ... integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts". Cancer ...
Domingo, R. J.; Reilly, R. M. (2000). "Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using ... The modified antibody accumulates in the tumour cells, concentrating the effects of the radioactivity of 90Y. Drugs containing ...
Adoptive cell transfer refers to the application of pre-stimulated, modified T cells or dendritic cells and is presently used ... Radioimmunotherapy of metastatic melanoma is currently under investigation. Radiotherapy has a role in the palliation of ... "Cell. 161 (7): 1681-1696. doi:10.1016/j.cell.2015.05.044. PMC 4580370. PMID 26091043.. ... Molecular basis for melanoma cell motility: actin-rich podosomes (yellow), along with cell nuclei (blue), actin (red), and an ...
... cell - cell differentiation - cell motility - cell proliferation - cell respiration - cell adhesion - cellular adoptive ... radioimmunotherapy - radioisotope - radiolabeled - radiologic exam - radionuclide scanning - radiopharmaceutical - ... systemic therapy T cell - T-3 - T-cell depletion - T-cell lymphoma - T138067 - T4N5 liposomal lotion - T900607 - TAC-101 - ... basal cell - basal cell carcinoma - basal cell nevus syndrome - basophil - batimastat - BAY 12-9566 - BAY 43-9006 - BAY 56-3722 ...
Here a, b and c are lattice constants, No is space group number and Z is the number of formula units per unit cell. Density was ... "Production of actinium-225 for alpha particle mediated radioimmunotherapy". Applied Radiation and Isotopes. 62 (5): 667-679. ... As a result, after the cancer cells were quickly killed by alpha particles from 225Ac, the radiation from the actinium and its ... Not only 225Ac itself, but also its daughters, emit alpha particles which kill cancer cells in the body. The major difficulty ...
Due to its mode of beta decay, iodine-131 is notable for causing mutation and death in cells that it penetrates, and other ... This occurs because when the radioactive iodine destroys the thyroid cells, they can release thyroid hormone into the blood ... Use of the 131I as iodide salt exploits the mechanism of absorption of iodine by the normal cells of the thyroid gland. ... is actively deposited into thyroid follicular cells. Studies involving healthy adult volunteers determined that at levels above ...
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that the Journal of Clinical Oncology has published the results ... A companion editorial discussed the growing evidence for the efficacy of radioimmunotherapy (RIT) in B-cell lymphomas. Cell ... Landmark Study Demonstrates Potential Of Radioimmunotherapy For Treatment Of Indolent B-Cell Non-Hodgkins Lymphoma. Published ... About Cell Therapeutics, Inc.. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an ...
Malignant plasma cells are very radiosensitive, but the potential role of radioimmunotherapy (RIT) in the management of ... A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.. [Damian J Green, Nural N Orgun, Jon C ... Furthermore, CD38 has not been explored as a RIT target despite its uniform high expression on malignant plasma cells. In this ... The vast majority of patients with plasma cell neoplasms die of progressive disease despite high response rates to novel agents ...
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma. This study has been ... Lymphoma, B-Cell. Interventions: Drug: cyclophosphamide. Drug: etoposide. Drug: rituximab. Drug: cytarabine. Drug: doxorubicin ... Cytarabine and Doxorubicin followed by radioimmunotherapy:Bexxar ...
Experimental Radioimmunotherapy of Murine Lymphoma with 131I-labeled Anti-T-Cell Antibodies. Christopher C. Badger, Kenneth A. ... Experimental Radioimmunotherapy of Murine Lymphoma with 131I-labeled Anti-T-Cell Antibodies ... Experimental Radioimmunotherapy of Murine Lymphoma with 131I-labeled Anti-T-Cell Antibodies ... Experimental Radioimmunotherapy of Murine Lymphoma with 131I-labeled Anti-T-Cell Antibodies ...
... of 131I-labelled monoclonal antibody 123C3 in human small-cell lung carcinoma xenografts established from the NCI-H69 cell line ... Radioimmunotherapy of small-cell lung cancer xenografts using 131I-labelled anti-NCAM monoclonal antibody 123C3 Cancer Immunol ... Regrowth of the tumours occurred in all cases and could not be attributed to loss of neural cell adhesion molecule (NCAM) ... We have studied the therapeutic efficacy of 131I-labelled monoclonal antibody 123C3 in human small-cell lung carcinoma ...
Pretargeted radioimmunotherapy (PRIT) allows for further improved targeting of tumor cells over standard directly labeled ... Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced ... This phase I trial studies pretargeted radioimmunotherapy and donor peripheral blood stem cell transplant employing fludarabine ... Full Chimerism is defined as , 95% donor CD3+ T cells and mixed chimerism is the detection of peripheral blood donor T cells ( ...
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell ... CD20 is a protein found on the cells of a type of cancer cell called B-cells. Anti-CD20 RIT attaches radioactive material to a ... Lymphoma, B-Cell. Lymphoma, Mantle-Cell. Burkitt Lymphoma. Lymphoma, Large B-Cell, Diffuse. Neoplasms by Histologic Type. ... Burkitt Lymphoma CD20-Positive Neoplastic Cells Present Diffuse Large B-Cell Lymphoma Indolent Non-Hodgkin Lymphoma Mantle Cell ...
A Phase I Study of Intraperitoneal Radioimmunotherapy with 131I-8H9 for Patients with Desmoplastic Small Round Cell Tumors and ... Phase 1 Study of Intraperitoneal Radioimmunotherapy with 131I-Burtomab for Patients with Desmoplastic Small Round Cell Tumors ... Radioactive iodine is bound to 8H9 to deliver radiation directly to the tumor to kill tumor cells. ... antibody 8H9 injected into the lining of the abdomen or peritoneum to treat patients with desmoplastic small round cell tumors ...
... notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapies... ... radioimmunotherapy-resistant diffuse large B-cell lymphoma (DLBCL) cell lines. The study identified cell cycle kinase ... Nordic Nanovector: Additional Preclinical Studies With CD37-targeting Radioimmunotherapies for B-cell Malignancies Presented at ... Cell: +44-7561-431-762. Email: [email protected] International Media Enquiries. Mark Swallow/David Dible (Citigate Dewe ...
Cell Lung Cancer. Intervention. 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and ... 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer ( ... 131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer ( ... "131I-L19SIP Radioimmunotherapy Combined With Radiochemotherapy in Patients With Locally-advanced Non Small Cell Lung Cancer ( ...
CONCLUSION Nonmyeloablative radioimmunotherapy with 131I-anti-B1 is associated with a high rate of durable remissions in ... in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS Patients were first given tracelabeled ... PURPOSE The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, ... patients with B-cell lymphoma refractory to chemotherapy. ... Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.. @ ...
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and ... Desmoplastic small round cell tumor (DSRCT), a rare sarcoma of adolescents/young adults primarily involving the peritoneum, has ... B7H3 is expressed on DSRCT cell surface, providing a target for antibody-based immunotherapy.In this phase I study, we ... evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 ...
Radioimmunotherapy (RIT) Radioimmunotherapy (RIT) combines radiation therapy with monoclonal antibodies, a type of ... Radiation can be given directly to cancer cells and so less radiation goes to nearby normal tissue. But internal radiation ... Monoclonal antibodies can interfere with a cells function or can be used to carry drugs, toxins or radioactive material ... Monoclonal antibodies specifically target cancer cells. When a RIT is injected into the body, the monoclonal antibody delivers ...
N2 - Radioimmunotherapy is the targeted delivery of cytocidal radiation to cells via specific antibody. Although mature for the ... AB - Radioimmunotherapy is the targeted delivery of cytocidal radiation to cells via specific antibody. Although mature for the ... Radioimmunotherapy is the targeted delivery of cytocidal radiation to cells via specific antibody. Although mature for the ... abstract = "Radioimmunotherapy is the targeted delivery of cytocidal radiation to cells via specific antibody. Although mature ...
"Is radioimmunotherapy before a donor peripheral blood stem cell transplant an effective treatment for non-Hodgkins Lymphoma?" ... Zevalin (radioimmunotherapy) before stem cell transplant in treating patients with non-Hodgkins lymphoma ... mantle cell, diffuse large B cell, small lymphocytic lymphoma) and CD20+ Hodgkins disease for which standard curative therapy ... A monoclonal antibody uses the bodys own immune cells to kill cancer cells. Patients remain at high risk of lymphoma returning ...
Lymphoma is a cancer of the immune system and white blood cells. The two main types are Hodgkin lymphoma and non-Hodgkin ... Radioimmunotherapy: This delivers high-powered radioactive doses directly into the cancerous B-cells and T-cells to destroy ... for some folks, a stem cell transplant (using non-controversial adult stem cells) is curative.) Go to an expert on Lymphoma, ... Classic Hodgkin lymphoma is marked by the presence of cells known as Reed-Sternberg cells. Other subtypes affect different ...
New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study A new alpha-radioimmunotherapy, 212Pb-anti ... New strategy may help guard beta cells, slow the onset of type 1 diabetes Type 1 diabetes occurs when a persons own immune ... Study shows interferons do not induce the expression of SARS-CoV-2 cell entry receptor In a new bioRxiv study, authors ... Study shows fused lung cells are pervasive in severe COVID-19 In a recent bioRxiv paper, scientists from Institut Pasteur and ...
Stem Cells.. [James O Armitage; Karen H Antman] -- The Third Edition of this comprehensive reference has been overhauled, with ... 6 Radioimmunotherapy; 7 Immune Adjuvant Therapy Post High-Dose Therapy. 8 A Health Policy Perspective on High-Dose Cancer ... cells> ;. schema:name "High-Dose Cancer Therapy : Pharmacology, Hematopoietins, Stem Cells."@en ;. schema:productID "913799496 ... 19 Negative and Positive Stem Cell Selection; 20 Stem Cell In Vitro Purging for Autologous Transplantation; Growth Factors; 21 ...
... bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. The ... growth and differentiation of the bound cells into mature and functional endothelial cells on the surface of the device to ... coating on the device can also contain a compound or growth factor for promoting the progenitor endothelial cell to accelerate ... Targeted radioimmunotherapy. US5945457 *. 1 Oct 1997. 31 Aug 1999. A.V. Topchiev Institute Of Petrochemical Synthesis, Russian ...
Cell Death Pathways in Photodynamic Therapy of Cancer. Previous Article in Journal. Targeting the Mammalian Target of Rapamycin ...
... is a surrogate for B cell malignancy (indicates malignant B cells). Percent change from Visit 2 (Week 0, Baseline) = (value at ... is a surrogate for B cell malignancy (indicates malignant B cells). Percent change from Visit 2 (Week 0, Baseline) = (value at ... HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab. The safety and ... Leukemia, B-Cell. Fludarabine. Fludarabine phosphate. Alemtuzumab. Ofatumumab. Antineoplastic Agents. Antimetabolites, ...
This Phase I/II radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic ... This Phase I/II radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic ... Thirty-three patients with measurable metastatic renal cell carcinoma were treated. Groups of at least three patients received ...
Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for ... Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 48:297-304. ... or animal cells such as fibroblasts, CHO cells, COS cells, NS0 cells, HeLa cells, BHK cells, HEK 293 cells, or human cells. ... subtilis cells, fungal cells such as yeast cells or Aspergillus cells, insect cells such as Drosophila S2 or Spodoptera Sf9 ...
Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the ... Diffuse Large B-Cell Lymphoma (Non-Hodgkin Lymphoma) Treatment Protocols * Sections Diffuse Large B-Cell Lymphoma (Non-Hodgkin ... Axicabtagene ciloleucel 2 x 10^6 CAR-positive viable T cells/kg body weight, not to exceed 2 x 10^8 CAR-positive viable T cells ... Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017 Dec 28. 377 (26):2545-2554. [Medline]. ...
Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or ... of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with subcutaneous renal cell cancer (RCC) ... Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the stability, biodistribution, and therapeutic ...
Doxorubicin combined with a radioimmunotherapy increased tail DNA in the RPMI 8226 cell line but not the LP1or U266 cell lines ... Mechanisms of Cell Sensitization to Alpha-Radioimmunotherapy by Doxorubicin or Paclitaxel in MultipleMyeloma Cell Lines. ... and radioimmunotherapy with a radionuclides. Experimental Design:Threemultiplemyeloma cell lines (LP1, RMI 8226, and U266)were ... Both cell cycle arrest in the G2-M phase and an increase in DNA double-strand breaks could lead to radiosensitization of cells ...
Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma. ... Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkins lymphoma.. ...
Radioimmunotherapy. Treatment with a radioactive substance that is linked to an antibody that will attach to the tumor when ... The Cell Cycle: Cyclins and Checkpoints. A depiction of the cell cycle and role that cyclins play in the process; this ... p53s Role in the Cell. Shows various roles that p53 plays in the cell to protect the genome of the organism.. View Quicktime ... A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells. ...
Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. A doctor who specializes in ... After attaching to the receptor, the drug enters the cell, allowing radiation to damage the tumor cell. Recently, the FDA ... Radioimmunotherapy. This is a type of systemic therapy. It uses monoclonal antibodies to deliver radiation directly to cancer ... It targets cancer cells remaining after the initial treatment.. When it is not possible to destroy all of the cancer, doctors ...
Hematopoietic Stem Cell Transplantation. *Targeted Radioimmunotherapy. *Consultations. *Posttreatment Follow-up. *Prognosis and ... This classification divides NHL into two groups: those of B-cell origin and those of T-cell/natural killer (NK)-cell origin. [ ... Hematopoietic Stem Cell Transplantation. Hematopoietic stem cell transplantation (HSCT) has a role in the treatment of ... Vinca alkaloids (eg, vincristine): These drugs inhibit cell growth and proliferation at the mitotic phase of the cell cycle. ...
  • Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that the Journal of Clinical Oncology has published the results of the First-line Indolent Trial (FIT) demonstrating that use of Zevalin(R)([90Y]-ibritumomab tiuxetan) in consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma provided important patient benefits including a significant improvement in progression free survival. (medicalnewstoday.com)
  • Zevalin is currently approved in the United States for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. (medicalnewstoday.com)
  • We have shown previously that 131 I-labeled antibodies against the Thy-1.1 differentiation antigen can cure AKR/Cum (Thy-1.2 + ) mice bearing AKR/J (Thy-1.1 + ) SL2 T-cell lymphoma. (aacrjournals.org)
  • The preclinical studies investigated the dose-dependent efficacy and tolerability of 212Pb-NNV003 in human cell and mouse models of chronic lymphocytic leukaemia (CLL) and Burkitt's lymphoma (a type of non-Hodgkin's lymphoma, NHL). (prnewswire.co.uk)
  • The poster describes results from a preclinical study aimed at identifying possible drug combinations involving Betalutin® in two aggressive, radioimmunotherapy-resistant diffuse large B-cell lymphoma (DLBCL) cell lines. (prnewswire.co.uk)
  • Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. (semanticscholar.org)
  • article{Kaminski1996Iodine131antiB1RF, title={Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. (semanticscholar.org)
  • We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. (semanticscholar.org)
  • Is radioimmunotherapy before a donor peripheral blood stem cell transplant an effective treatment for non-Hodgkin's Lymphoma? (studypages.com)
  • Clinically, grade 3B follicular lymphoma is treated like diffuse large B-cell lymphoma . (medscape.com)
  • These medications were the first agents of radioimmunotherapy, and they were approved for the treatment of refractory non-Hodgkin's lymphoma . (wikipedia.org)
  • Treatment recommendations for patients with diffuse large B-cell lymphoma (DLBCL) begin with evaluating the extent of the disease, performance status of the patient, and histologic subtypes. (medscape.com)
  • Follicular lymphoma is an indolent, or slow growing, lymphoma that starts in the B lymphocytes, white blood cells that make antibodies to fight infection. (healthcentral.com)
  • Radioimmunotherapy is sometimes used to treat follicular lymphoma that has relapsed, is treatment-resistant, or has responded in part or completely to first-line treatment. (healthcentral.com)
  • Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. (elsevier.com)
  • Fingerprint Dive into the research topics of 'Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. (elsevier.com)
  • Freeman, LM & Blaufox, MD 2004, ' Yttrium 90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy for B-Cell Non-Hodgkin's Lymphoma: Letter from the Editors ', Seminars in nuclear medicine , vol. 34, no. 1 SUPPL.1. (elsevier.com)
  • Patients diagnosed with B-cell lymphoma were treated with (131)I-labelled monoclonal antibodies (LL2, anti-CD22). (nih.gov)
  • Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. (nih.gov)
  • VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that data presented at the 12th Congress of EHA in Vienna, Austria, showed positive responses in patients with non-Hodgkin's lymphoma (NHL) treated with a new radioimmunotherapy (RAIT) using epratuzumab to deliver toxic radiation directly to lymphoma cells in small fractions. (drugs.com)
  • The internalizing property of epratuzumab is believed to be well suited for delivering radiation from the potent radioisotope, yttrium-90, selectively and locally to lymphoma cells that express the CD22 antigen. (drugs.com)
  • Sixty-eight percent of patients with follicular lymphoma responded to the RAIT, compared to 57% for mantle cell lymphoma, 22% for diffuse large B-cell lymphoma, and all 3 patients with marginal zone lymphoma. (drugs.com)
  • This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell non-Hodgkin lymphoma that has returned after a period of improvement. (mayo.edu)
  • It is not yet known whether 90-yttrium ibritumomab tiuxetan and BEAM before a stem cell transplant are more effective than BEAM alone in treating patients with diffuse large b-cell non-Hodgkin lymphoma. (mayo.edu)
  • Patients with CD20 positive diffuse large B-cell lymphoma as confirmed by a pathological biopsy report. (mayo.edu)
  • 131 I-Tositmomab Myeloablative Radioimmunotherapy for Non-Hodgkin Lymphoma: Radiation Dose to Testes. (swedish.org)
  • Zevalin and Bexxar are FDA approved to treat follicular B-cell non-Hodgkin's lymphoma. (fortherecordmag.com)
  • 1995) A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. (springer.com)
  • Cohorts of three to six patients with B-cell lymphoma received 185 MBq/m 2 [ 90 Y]epratuzumab with unconjugated epratuzumab (total protein dose 1.5 mg/kg) once weekly for two to four infusions, with [ 111 In]epratuzumab coadministered at first infusion for scintigraphic imaging and dosimetry. (aacrjournals.org)
  • Radioimmunotherapy with weekly 185 MBq/m 2 [ 90 Y]epratuzumab achieved a high objective response rate (62%) across lymphoma subtypes, including durable CRs. (aacrjournals.org)
  • In this study, we explored the efficacy and toxicity of a combination of two IC therapies, radioimmunotherapy (RIT) and immunotoxin (IT) therapy, to treat advanced, disseminated human lymphoma in immunodeficient mice. (aacrjournals.org)
  • There are also numerous well-characterized, lineage-restricted antigens on lymphoma cells, and the normal lymphocytes killed during therapy are replaced. (aacrjournals.org)
  • Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL), comprising about 6% of NHL cases. (wikipedia.org)
  • in the United States with mantle cell lymphoma. (wikipedia.org)
  • MCL is a subtype of B-cell lymphoma, due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. (wikipedia.org)
  • Mantle cell lymphoma has been reported in rare cases to be associated with severe allergic reactions to mosquito bites. (wikipedia.org)
  • In several of these cases, the mosquito bite allergy (MBA) reaction occurred prior to the diagnosis of MCL suggesting that MBA can be a manifestation of early developing, and therefore a harbinger of mantle cell lymphoma. (wikipedia.org)
  • Cyclin D1 negative mantle cell lymphoma can be diagnosed by detecting SOX11 marker. (wikipedia.org)
  • The workup for Mantle cell lymphoma is similar to the workup for many indolent lymphomas and certain aggressive lymphomas. (wikipedia.org)
  • Mantle cell lymphoma is a systemic disease with frequent involvement of the bone marrow and gastrointestinal tract (generally showing polyposis in the lining). (wikipedia.org)
  • medical citation needed] Since mantle cell lymphoma may present a lymphomatous polyposis coli and colon involvement is common, colonoscopy is now[when? (wikipedia.org)
  • Presents a case report regarding the administration of recombinant alpha interferon for the treatment of cutaneous T-cell lymphoma. (ebscohost.com)
  • The drug can be used as an anticancer drug in the treatment of hairy cell leukemia, myelogenous leukemia, certain renal cell lymphoma, follicular non-Hodgkin's lymphoma, as an adjunct to. (ebscohost.com)
  • Presents several therapeutic approaches for the treatment of cutaneous T-cell lymphoma. (ebscohost.com)
  • Determine the maximum tolerated dose of iodine I 131 monoclonal antibody Lym-1 in patients with previously treated diffuse large cell lymphoma. (knowcancer.com)
  • Radioimmunotherapy is being used to treat some types of cancer, such as lymphoma. (cancer.gov)
  • Radioimmunotherapy with Zevalin(R) (Ibritumomab Tiuxetan), approved for follicular, low grade NHL which relapsed following 1st line rituximab based therapy, allows high doses of lymphoma-targeted radiation with lower doses to normal tissues. (bio-medicine.org)
  • Lymphoma histologies included diffuse B cell (n=20), mantle cell (n=13), follicular (n=4) and transformed (n=4). (bio-medicine.org)
  • Another drug, called rituximab (Rituxan), is often used to treat B-cell non-Hodgkin's lymphoma. (northside.com)
  • People with lymphoma that returns after treatment or does not respond to treatment may receive high-dose chemotherapy followed by a bone marrow transplant (using stem cells from yourself). (northside.com)
  • Rituximab (Rituxan) is a chimeric monoclonal antibody that targets the CD20 anti-gen on normal and malignant non-Hodgkin's lymphoma (NHL) cells. (cancernetwork.com)
  • Rituximab (IDEC-C2B8 [Rituxan]) is a chimeric anti-CD20 monoclonal antibody (MoAb) that was recently approved by the FDA for the treatment of patients with low-grade or follicular B-cell non-Hodgkin's lymphoma. (cancernetwork.com)
  • Zevalin is indicated for the treatment of relapsed or refractory low grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL). (centerwatch.com)
  • Two new dual-action radioimmunotherapy agents, Bexxar and Zevalin, are now available as outpatient therapies to some patients with low-grade or transformed non-Hodgkin's lymphoma at the University of Miami Sylvester Comprehensive Cancer Center. (sylvester.org)
  • CHICAGO, June 3, 2007- Patients treated for follicular lymphoma, a slow-growing type of non-Hodgkins lymphoma, may benefit from chemotherapy followed by radioimmunotherapy, according to a University of Pittsburgh Medical Center (UPMC) study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago and published as Abstract 8005 in the ASCO proceedings. (upmc.com)
  • Radioimmunotherapy was delivered through the use of a radiolabeled monoclonal antibody specifically designed to kill lymphoma cells with the help of a radioactive atom. (upmc.com)
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (mdanderson.org)
  • Lymphoma is a general term for cancers that develop in the lymphatic system (the tissues and organs that produce, store and carry white blood cells). (mdanderson.org)
  • Hodgkin's disease is a type of lymphoma that develops in white blood cells. (mdanderson.org)
  • Lymphomas that do not start in white blood cells are called non-Hodgkin's lymphoma. (mdanderson.org)
  • Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. (semanticscholar.org)
  • Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. (semanticscholar.org)
  • The Alvin & Lois Lapidus Cancer Institute at LifeBridge Health is currently participating in a study on the effect of Zevalin, an investigational radioimmunotherapy, in lymphoma patients who already have failed other treatment for the disease. (lifebridgehealth.org)
  • B-cell lymphoma is a type of blood cancer that commonly forms in the lymph glands but may also form in the spleen, bone marrow, blood or other areas of the body. (mainlinehealth.org)
  • The majority of B-cell lymphomas are non-Hodgkin lymphoma, the more common types being diffuse large B-cell lymphoma (DLBCL), which is usually aggressive (fast moving), and follicular lymphoma, which is usually indolent (slow moving). (mainlinehealth.org)
  • Whether your cancer is moving quickly or slowly is the most important factor in determining treatment for your B-cell lymphoma. (mainlinehealth.org)
  • The sample is analyzed to look for non-Hodgkin's lymphoma cells. (mayoclinic.org)
  • SEATTLE, Oct. 2 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular non-Hodgkin's lymphoma. (bio-medicine.org)
  • Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. (bio-medicine.org)
  • Each year, thousands of people develop blood diseases, such as leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma that are treatable with blood stem cell or bone marrow transplants. (mercy.com)
  • When H/DS is associated with an indolent B-cell leukemia/lymphoma, either metachronous or concurrent, the issue of its clonal relationship with the primary B-cell neoplasm is raised. (thefreedictionary.com)
  • The repeat biopsy led to a final pathologic diagnosis of a low-grade B-cell lymphoma consistent with marginal-zone lymphoma (figure 2). (thefreedictionary.com)
  • The single-agent phase II study is designed to assess the antitumor activity, tolerability and pharmacokinetic profile of SGN-40 in patients with relapsed or refractory diffuse large B-cell lymphoma. (thefreedictionary.com)
  • In Zurich, we regularly screen all B-cell lymphoma patients by serology and by PCR [polymerase chain reaction] of a biopsy specimen for Borrelia burgdorferi, and occasionally, we do see regression of Borrelia-positive B-cell lymphomas upon doxycycline-based therapy over 3-6 weeks," explained Dr. (thefreedictionary.com)
  • Senesco" or the "Company") (NYSE MKT: SNT) reported today that the clinical trial of SNS01-T has been expanded to include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL). (thefreedictionary.com)
  • The purpose of the study is to assess the response rate of patients with relapsed or refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy (XRT). (stanford.edu)
  • PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with stage II, stage III, or stage IV diffuse large B-cell non-Hodgkin's lymphoma. (stanford.edu)
  • Both Hodgkin's disease (sometimes referred to as Hodgkin's lymphoma) and non-Hodgkin's lymphoma are cancers that originate in a type of white blood cell known as a lymphocyte, an important component of the body's immune system. (medicinenet.com)
  • The type of abnormal cells identified in the sample determines whether a lymphoma is classified as Hodgkin's disease or non-Hodgkin's lymphoma. (medicinenet.com)
  • Non-Hodgkin's lymphoma is a type of cancer that originates in the cells of the lymphatic and immune systems, such as the blood cells known as lymphocytes and the lymph node tissues. (medicinenet.com)
  • The presence of characteristic cells called Reed-Sternberg cells would indicate a Hodgkin's lymphoma. (medicinenet.com)
  • Has developed translational laboratory pre-clinical models for cancer vaccines, CAR T cells, novel combinatorial strategies, targeted therapies for T cell lymphoma, thrombosis and cancer. (bethematch.org)
  • These studies suggest that radiolabeled antibodies against differentiation antigens may be useful for therapy in spite of binding to normal cell populations but curative therapy may require infusion of unirradiated bone marrow. (aacrjournals.org)
  • Radiolabeled monoclonal antibodies can be combined with fludarabine phosphate and TBI to find cancer cells and kill them without harming normal cells. (clinicaltrials.gov)
  • Pretargeted radioimmunotherapy (PRIT) allows for further improved targeting of tumor cells over standard directly labeled antibodies. (clinicaltrials.gov)
  • PURPOSE The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. (semanticscholar.org)
  • Radioimmunotherapy (RIT) combines radiation therapy with monoclonal antibodies , a type of immunotherapy. (cancer.ca)
  • Monoclonal antibodies specifically target cancer cells. (cancer.ca)
  • In radioimmunotherapy (RIT), which has been used for a while to treat cancer , antibodies charged with radioactive isotopes target and destroy cancer cells. (medicalnewstoday.com)
  • For this test, they used a lab model of the blood-brain barrier made with human cells and discovered that the same radioisotope-charged antibodies used in earlier experiments could destroy HIV-infected cells in the brain without damaging the barrier. (medicalnewstoday.com)
  • Compositions and methods are provided for producing a medical device such as a stent, a stent graft, a synthetic vascular graft, heart valves, coated with a biocompatible matrix which incorporates antibodies, antibody fragments, or small molecules, which recognize, bind to and/or interact with a progenitor cell surface antigen to immobilize the cells at the surface of the device. (google.ca)
  • Radioimmunotherapy (RIT) utilizes antibodies to direct radionuclides to specific antigens within the tumor. (springeropen.com)
  • Current RAIT treatments for NHL such as tositumomab and ibritumomab tiuxetan are radiolabeled murine antibodies targeting the CD20 antigen on the surface of mature B-cells and B-cell tumors as expressed by NHL cells. (drugs.com)
  • It uses monoclonal antibodies -- cells the immune system recruits to identify and neutralize antigens -- designed to recognize and bind to specific cell antigens. (auntminnie.com)
  • Radioactive substances linked to monoclonal antibodies, such as 90-yttrium ibritumomab tiuxetan, can bind to cancer cells and give off radiation which may help kill cancer cells. (mayo.edu)
  • Radioimmunotherapy uses antibodies "tagged" with a cancer-killing substance. (hopkinsmedicine.org)
  • These tagged antibodies recognize tumor cells and bind with them, thus bringing the cancer-killing medicine directly to the tumor tissue. (hopkinsmedicine.org)
  • 1999) Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. (springer.com)
  • Conventional radioimmunotherapy (RIT) uses antibodies directly radiolabled to specifically deliver radiation to kill cancer cells. (fredhutch.org)
  • Pretargeted RIT enhances the efficacy of radioimmunotherapy by first using streptavidin-labeled antibodies to label the tumors. (fredhutch.org)
  • Radioimmunotherapy (RIT) can be used to selectively kill cancer cells before transplant, by delivering targeted doses of radiation conjugated to antibodies that recognize cell surface proteins specific to malignant cells. (fredhutch.org)
  • Although radioimmunotherapy approaches with two or more infusions have been explored clinically using murine antibodies in B-cell malignancies ( 13 , 14 ), immunogenicity might limit the potential for continued application, and there have been no reports of fractionated studies extending these treatment regimens. (aacrjournals.org)
  • Radioactive antibodies that target cancer cells are used for medical diagnostics with PET imaging or for targeted radioimmunotherapy. (bionity.com)
  • Previously we reported the use of anti-idiotype antibodies in the therapy of patients with B-cell malignancies. (semanticscholar.org)
  • Radioimmunotherapy combines immunotherapy, the targeted use of monoclonal antibodies created in the laboratory, with radiation therapy distributed in an intense, highly targeted manner. (lifebridgehealth.org)
  • B cells produce antibodies and help our bodies fight infection. (mainlinehealth.org)
  • Immunotherapy uses laboratory-made monoclonal antibodies to target and kill cancer cell. (epnet.com)
  • a LYMPHOCYTE formed in the bone marrow of mammals that, after stimulation with a particular ANTIGEN , divides to produce daughter cells that manufacture large amounts of ANTIBODIES which are passed into the bloodstream. (thefreedictionary.com)
  • Type of white blood cell that produces antibodies. (thefreedictionary.com)
  • Monoclonal antibodies such as rituximab and yttrium 90-Yttrium ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells. (stanford.edu)
  • The complement system can be specifically targeted to tumor cells due to molecular changes on their surfaces that are recognized by complement directly or via naturally occurring antibodies. (biomedsearch.com)
  • Cell Therapeutics has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for use of Zevalin in first-line consolidation therapy based on the FIT data. (medicalnewstoday.com)
  • Zevalin is a radioimmunotherapy. (studypages.com)
  • SILBERNER: Zevalin is a type of radioimmunotherapy. (npr.org)
  • Zevalin or Bexxar) [Patients who have received prior anti-B-cell monoclonal antibody therapy (e.g., rituximab or epratuzumab) will NOT be excluded. (knowcancer.com)
  • The promise of utilizing targeted radioimmunotherapy together with high-dose chemotherapy prior to autologous stem-cell transplant is an exciting new potential application of Zevalin. (bio-medicine.org)
  • ZEVALIN(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. (bio-medicine.org)
  • In February 2002, Zevalin was the first radioimmunotherapy to receive FDA approval. (centerwatch.com)
  • Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidati. (bio-medicine.org)
  • Approval would make Zevalin only Radioimmunotherapy in U.S. to be Indi. (bio-medicine.org)
  • If approved, Zevalin would be the only radioimmunotherapy in the U.S. with approval for use as first-line consolidation therapy. (bio-medicine.org)
  • If the sBLA is approved there would be approximately 18,000 additional patients that currently receive first-line treatment that would potentially be eligible to use Zevalin under the proposed expanded label," said James A. Bianco, M.D., CEO of Cell Therapeutics. (bio-medicine.org)
  • Extensive clinical studies of ZEVALIN have confirmed high response rates and durable responses in patients with relapsed, refractory follicular or transformed B-cell NHL. (thefreedictionary.com)
  • A companion editorial discussed the growing evidence for the efficacy of radioimmunotherapy (RIT) in B-cell lymphomas. (medicalnewstoday.com)
  • Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas. (semanticscholar.org)
  • Most lymphomas start in a type of white blood cell called the B lymphocyte, or B cell. (medlineplus.gov)
  • Tomblyn M. Radioimmunotherapy for B-cell non-hodgkin lymphomas. (springer.com)
  • The new golden era for radioimmunotherapy: not just for lymphomas anymore. (springer.com)
  • Advances in Hematopoietic Stem Cell Transplantation (HSCT) in Childhood and Adolescent Lymphomas. (swedish.org)
  • Tositumomab and 131I Tositumomab) for treatment of relapsed or residual CD20 antigen-expressing B-cell lymphomas following ASCT. (knowcancer.com)
  • Idiotypes are distinct clonal markers for B-cell lymphomas. (semanticscholar.org)
  • For lymphomas, which typically invade the bone marrow and are unreachable by standard radiation, radioimmunotherapy reaches the inside of the bone marrow through the bloodstream. (lifebridgehealth.org)
  • Follicular lymphomas originate in B lymphocytes (B cells) in lymph nodes. (primeoncology.org)
  • IVL continues to present diagnostic challenges due to its elusive and diverse pathologic and clinical findings, and according to Ponzoni and colleagues (9), a comprehensive analysis is needed to find analogies and differences between the intravascular and extravascular components of large B-cell lymphomas to further characterize them and potentially formulate more focused treatment depending on each patient's unique presentation. (thefreedictionary.com)
  • Dr Axel Kallies, Associate Professor David Tarlinton, Dr Stephen Nutt and colleagues made the discovery while investigating the development of B-cell lymphomas. (thefreedictionary.com)
  • Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. (nih.gov)
  • In this report, both conventional RIT (directly radiolabeled antibody) and streptavidin-biotin pretargeted RIT (PRIT) directed against the CD38 antigen were assessed as approaches to deliver radiation doses sufficient for multiple myeloma cell eradication. (sigmaaldrich.com)
  • Doses of 0.5-5.0 mg antibody saturated cells in the spleen but only slightly increased the proportion of antibody in tumor. (aacrjournals.org)
  • We have studied the therapeutic efficacy of 131I-labelled monoclonal antibody 123C3 in human small-cell lung carcinoma xenografts established from the NCI-H69 cell line in nude mice. (nih.gov)
  • The purpose of this study is to evaluate the safety of different dose levels of the radiolabelled antibody 8H9 injected into the lining of the abdomen or peritoneum to treat patients with desmoplastic small round cell tumors (DSCRT) or other solid peritoneal tumors. (mskcc.org)
  • The research collaboration was established in June 2015 with Orano Med (formerly known as AREVA Med) to develop and investigate a next-generation targeted alpha therapy, comprising Nordic Nanovector's chimeric anti-CD37 antibody (NNV003) and lead-212 (212Pb), for the treatment of B-cell malignancies. (prnewswire.co.uk)
  • B7H3 is expressed on DSRCT cell surface, providing a target for antibody-based immunotherapy.In this phase I study, we evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 murine monoclonal antibody 131I-omburtamab in patients with DSRCT or other B7H3-expressing tumors involving the peritoneum. (onmedica.com)
  • Radioimmunotherapy is the targeted delivery of cytocidal radiation to cells via specific antibody. (elsevier.com)
  • Nosanchuk, JD & Dadachova, E 2012, ' Radioimmunotherapy of fungal diseases: The therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens ', Frontiers in Microbiology , vol. 2, no. (elsevier.com)
  • A monoclonal antibody uses the body's own immune cells to kill cancer cells. (studypages.com)
  • This allows radiation to be brought straight to cancer cells to which the antibody attaches. (studypages.com)
  • The antibody selects the particular type of cancer cell and the attached radioisotope delivers a lethal dose of radiation that kills the target cell, while leaving untargeted (healthy) cells unharmed. (medicalnewstoday.com)
  • Time to next chronic lymphocytic leukemia (CLL) treatment is defined as the time from treatment allocation/randomization (Visit 2) until the time of the first administration of the next CLL treatment other than ofatumumab (or HuMaxCD20, a fully human monoclonal antibody to CD20 that is expressed on the surface of B-cells). (clinicaltrials.gov)
  • Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. (edu.au)
  • Radioimmunotherapy uses an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. (wikipedia.org)
  • [1] In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. (wikipedia.org)
  • The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. (wikipedia.org)
  • Dadachova E, Nosanchuk JD, Shi L, Schweitzer AD, Frenkel A, Nosanchuk JS, and Casadevall A. Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a monoclonal antibody to melanin. (wikipedia.org)
  • Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. (wikipedia.org)
  • NO:7 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:9, wherein said humanized antibody binds prostate stem cell antigen (PSCA), and wherein administration of said humanized antibody to a subject diagnosed with prostate cancer decreases tumor growth to a greater extent than treatment with the murine 1G8 monoclonal antibody. (google.co.uk)
  • Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. (ru.nl)
  • We tested the stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ((131)I, (88/90)Y, (177)Lu, and (186)Re) of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with subcutaneous renal cell cancer (RCC) tumors. (ru.nl)
  • Experimental Design:Threemultiplemyeloma cell lines (LP1, RMI 8226, and U266)were treatedwith 213Bi-radiolabeledB-B4, amonoclonal antibody that recognizes syndecan-1 (CD138) 24 hours after paclitaxel (1nmol/L) or doxorubicin (10 nmol/L) treatment.Cell survivalwas assessed using a clonogenic survival assay. (europa.eu)
  • The team has investigated the hypothesis that loading curcumin into nanoparticles (NPs) created to specifically target prostate cancer cells via an anti-PSMA antibody will improve the effectiveness of treatment due to tumor cell uptake of the NP-antibody complex. (army.mil)
  • In the same study, cyclosporin A, a substance known to have its major effects on T cells [ 3 - 8 ], was given to prevent the development of immune response to the therapeutic mouse/human chimeric antibody. (springeropen.com)
  • The OX-8 cell line (Health Protection Agency Culture Collections) producing a murine anti-CD8 monoclonal antibody was grown in CD Hybridoma Medium (Gibco, Life Technologies, Carlsbad, CA, USA) supplemented with 2 mM l -glutamine and 2.8 mg/L gentamicin (PAA Laboratories GmbH) for 10 to 12 days. (springeropen.com)
  • Background: The lupus-associated (La)-specific murine monoclonal antibody DAB4 (APOMAB®) specifically binds dead cancer cells. (edu.au)
  • This involves linking a radioactive substance to an antibody that targets the cancerous cells and injecting the substance into the body. (medlineplus.gov)
  • A radioactive compound is hooked to an antibody that latches on to cancer cells, delivering radiation directly to those cancer cells. (npr.org)
  • Immunomedics' epratuzumab is a humanized monoclonal antibody that targets the CD22 antigen on B-cells, including malignant B-cells. (drugs.com)
  • We previously investigated the potential of targeted radiotherapy using a bismuth-213 ( 213 Bi)-labeled anti-CD45 antibody to replace total body irradiation as conditioning for hematopoietic cell transplantation in a canine model. (aacrjournals.org)
  • Dadachova's team paired the monoclonal antibody mAb2556, designed to target a protein on the surface of HIV-infected cells, with the radionuclide bismuth-213. (auntminnie.com)
  • A key finding of the study was that the radiolabeled antibody crossed the blood-brain barrier and destroyed HIV-infected cells without any overt damage to the barrier itself, Dadachova said. (auntminnie.com)
  • 1989) Removal of neuroblastoma cells from bone marrow by a direct monoclonal antibody rosetting technique. (springer.com)
  • A clearing agent removes unbound antibody, and then radiolabeled-DOTA-biotin binds to the antibody to kill the cancer cells or is rapidly excreted in the urine, limiting the toxicity to normal cells. (fredhutch.org)
  • A clearing agent removes any unbound antibody, followed by infusion of a small molecule, radiolabeled-DOTA-biotin, that will bind to the streptavidin-antibody accumulated on cancer cells or will be rapidly cleared from the blood through urine (see figure). (fredhutch.org)
  • With mice bearing human cancer cells that are targeted by trastuzumab, they showed that for PET imaging the zirconium-labelled antibody worked as well as those produced via established methods. (bionity.com)
  • Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. (wikipedia.org)
  • The monoclonal antibody can bind to substances in the body, including cancer cells. (cancer.gov)
  • After infusion into a patient, the monoclonal antibody targets the CD20 antigen, which is found on the surface of mature B cells and B-cell tumors. (centerwatch.com)
  • The radiological agent is Iodine-131, a beta-isotope which is delivered right to tumor cells by the antibody. (sylvester.org)
  • By combining a monoclonal antibody that preferentially binds to CD20-positive B cells with radioactive iodine, Bexxar delivers the radiation dose to target B cells inside the body. (sylvester.org)
  • The radioactive agent then sends radioactivity several millimeters to the tumor, reaching cells that the antibody alone would never reach. (lifebridgehealth.org)
  • As the tumor cells begin dying, the monoclonal antibody can destroy even more cancerous cells. (lifebridgehealth.org)
  • This antibody will connect to a specific type of immune cell to protect these healthy cells from the radiation medication. (epnet.com)
  • PUBLIC HEALTH RELEVANCE: A novel approach to treat acute myeloid leukemia (AML), a blood cancer mainly seen in older people, uses an antibody called GO (a short term for gemtuzumab ozogamicin or Mylotarg") that recognizes leukemia cells and directs cell kill towards these cells while leaving most normal cells unaffected. (labome.org)
  • Combining a monoclonal antibody with combination chemotherapy and a radiolabeled monoclonal antibody may kill more cancer cells. (stanford.edu)
  • Because epidermal growth factor receptor (EGFR) is highly overexpressed on the surface of head and neck squamous cell carcinoma (HNSCC), we sought to determine if fluorescently labeled anti-EGFR antibody could be used to image HNSCC xenografts in vivo . (aacrjournals.org)
  • Antibody discovery via multiplexed single cell characterization. (biomedsearch.com)
  • The secreted immunoglobulin footprint of single hybridoma cells, containing ~10 fg of antibody purified in situ, has been probed for 9 properties concurrently by use of detection labels comprising 280 nm combinatorially colored fluorescent latex beads functionalized with proteins. (biomedsearch.com)
  • Immunotherapy has revolutionized cancer treatment by stimulating the patient's own immune system to attack cancer cells, yielding remarkably quick and complete remission in some cases. (news-medical.net)
  • Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. (google.co.uk)
  • 2000) In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors. (springer.com)
  • Radioimmunotherapy (RIT) is a combination of radiation therapy and immunotherapy. (epnet.com)
  • RIT has the benefits of immunotherapy the ability to deliver a high dose of radiation directly to cancer cells. (epnet.com)
  • Management strategies include surveillance, combination chemoimmunotherapy, radio-immunotherapy, and autologous or allogeneic hematopoietic cell transplantation (HCT). (hindawi.com)
  • Involved in radioimmunotherapy and tumor immunotherapy research. (bethematch.org)
  • Malignant plasma cells are very radiosensitive, but the potential role of radioimmunotherapy (RIT) in the management of plasmacytomas and multiple myeloma has undergone only limited evaluation. (sigmaaldrich.com)
  • A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of the Journal of Nuclear Medicine. (news-medical.net)
  • Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment. (news-medical.net)
  • Our goal is to conduct clinical trials with radioimmunotherapy targeting CD38 in multiple myeloma. (fredhutch.org)
  • A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. (sigmaaldrich.com)
  • This phase I/II trial studies the side effects and best dose of anti-cluster of differentiation (CD)20 radioimmunotherapy (RIT), and to see how well it works when given before chemotherapy and stem cell transplant in treating patients with B-cell malignancies that have not responded to treatment or have come back after responding to treatment. (clinicaltrials.gov)
  • Adding anti-CD20 to standard chemotherapy and stem cell transplant may be more effective in treating patients with B-cell malignancies. (clinicaltrials.gov)
  • These results identify B7-H3 as a compelling therapeutic target for this largely incurable pediatric tumor and demonstrate important advantages of locoregional compared to systemic delivery of CAR T cells for the treatment of CNS malignancies. (nature.com)
  • Its potential efficacy in other B-cell malignancies is currently being explored. (cancernetwork.com)
  • Anti-CD20 RIT attaches radioactive material to a drug that is designed to target CD20, which brings radioactive material to the cancer cells to kill the cells. (clinicaltrials.gov)
  • Radioactive iodine is bound to 8H9 to deliver radiation directly to the tumor to kill tumor cells. (mskcc.org)
  • Radioactive drugs can also be designed to kill tumors by delivering a radioactive payload specifically to the cancer cells. (bionity.com)
  • The radioactive substance gives off radiation, which may help kill cancer cells. (cancer.gov)
  • The two most common radioactive agents used today in radioimmunotherapy are Yitrium90 and Iodine131. (lifebridgehealth.org)
  • Radioisotope therapy travels through the blood to reach cells all over the body (systemic radiation). (cancer.ca)
  • Although highly active antiretroviral therapy (HAART) kills human immunodeficiency virus ( HIV ) in the bloodstream, it does not completely eliminate it from the body because the virus can linger in infected cells and replicate. (medicalnewstoday.com)
  • High-Dose Cancer Therapy : Pharmacology, Hematopoietins, Stem Cells. (worldcat.org)
  • I thought you might be interested in this item at http://www.worldcat.org/oclc/913799496 Title: High-Dose Cancer Therapy : Pharmacology, Hematopoietins, Stem Cells. (worldcat.org)
  • Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. (cancer.net)
  • Radiation therapy, sometimes called radiotherapy, x-ray therapy radiation treatment, cobalt therapy, electron beam therapy, or irradiation uses high energy, penetrating waves or particles such as x rays, gamma rays, proton rays, or neutron rays to destroy cancer cells or keep them from reproducing. (encyclopedia.com)
  • The purpose of radiation therapy is to kill or damage cancer cells. (encyclopedia.com)
  • Radiation therapy is often not appropriate for pregnant women, because the radiation can damage the cells of the developing baby. (encyclopedia.com)
  • Lead author Ekaterina Dadachova, PhD, of Albert Einstein College of Medicine, and colleagues investigated whether radioimmunotherapy could destroy remaining HIV-infected cells in blood samples of patients treated with antiretroviral therapy. (auntminnie.com)
  • The team applied radioimmunotherapy to blood samples from 15 HIV patients treated with highly active antiretroviral therapy at the Einstein-Montefiore Center for AIDS Research. (auntminnie.com)
  • Radioimmunotherapy (RIT) as a single agent therapy in patients with CD20 antigen-expressing relapsed or refractory low-grade, follicular, or transformed NHL has demonstrated overall response rates of 60-80% and has been approved by the FDA for use in this setting. (knowcancer.com)
  • Radiation therapy uses specific forms of radiation to kill or shrink cancer cells. (epnet.com)
  • Consolidation therapy is a treatment given after initial induction therapy and is aimed to improve the quality of the patient response by further diminishing the number of cancer cells with the goal of extending the response duration. (bio-medicine.org)
  • HMPL-523 is an oral small molecule therapy targeting Syk, a major component in the B-cell signalling pathway. (thefreedictionary.com)
  • The purpose of this study is to determine whether [18F]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. (stanford.edu)
  • Depending on the stage and type of NHL, treatment can include chemotherapy , biological therapy , stem cell transplant, and/or radiation therapy . (medicinenet.com)
  • I. To estimate the maximum tolerated dose (MTD) of 90Y activity that can be delivered via pretargeted radioimmunotherapy (PRIT) using B9E9-fusion protein (B9E9-FP), clearing agent (CA), and radiolabeled tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-biotin when followed by carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy and autologous stem cell transplantation. (clinicaltrials.gov)
  • Patients who are candidates for autologous stem-cell transplantation due to primary refractory or first relapse of disease. (mayo.edu)
  • This treatment is called targeted radioimmunotherapy. (bionity.com)
  • Giving chemotherapy drugs, such as fludarabine phosphate, and TBI before a donor peripheral blood stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. (clinicaltrials.gov)
  • In previous work, Prof. Dadachova had already managed to use the approach in the lab to target and destroy human immune cells infected with HIV. (medicalnewstoday.com)
  • Type 1 diabetes occurs when a person's own immune system destroys insulin-producing beta cells in the pancreas. (news-medical.net)
  • In recent years, scientists have learned how to grow large volumes of replacement beta cells, but the researchers are still trying out many options to protect these cells against the immune attack. (news-medical.net)
  • Depletion of CD8-positive cells during RIT in an immunocompetent rat tumor model might influence the number of animals developing metastases, indicating that the immune system may be important in the long-term outcome of RIT. (springeropen.com)
  • The brown staining illustrates the immune cell markers and the blue staining illustrates the cell nuclei. (springeropen.com)
  • 1998) IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. (springer.com)
  • It is a branch of immunology that studies interactions between the immune systems and the cancer cells. (omicsonline.org)
  • 3D cultured NB cells were also evaluated for the constitutive and IFN-γ-induced expression of surface molecules capable of tuning the anti-tumor activity of NK cells including immune checkpoint ligands. (frontiersin.org)
  • Thus, based on our results, 3D alginate-based hydrogels might represent a clinical-relevant cell culture platform where to test the efficacy of personalized therapeutic approaches aimed to optimize the current and innovative immune based therapies in a very systematic and reliable way. (frontiersin.org)
  • With radiation lasting a few hours or days and that travels a very short distance in tissue, cancer cells are targeted and "zapped" as healthy cells and the immune system are spared. (menstuff.org)
  • While eliminating a major class of immune cells sounds drastic, scientists have unexpectedly found that B-cell depletion doesn't leave the human body vulnerable to infectious disease. (thefreedictionary.com)
  • Indeed, upon microbial contact and stimulation by inflammatory cytokines DCs take up antigens and migrate from peripheral tissues, via the afferent lymphatics, into the T cell area of the draining lymph node where they present the antigens to T lymphocytes, thus triggering the immune response. (rupress.org)
  • I take care of children with Wilms' tumors , neuroblastoma , liver tumors, desmoplastic small round cell tumors , sarcomas , melanomas and thyroid tumors. (mskcc.org)
  • We have special expertise in performing large, complicated surgeries, with exceptional experience in surgery for neuroblastoma and desmoplastic small round cell tumors as well as complex liver surgery and thyroid surgery. (mskcc.org)
  • I also lead clinical trials, such as one assessing radioimmunotherapy for desmoplastic small round cell tumors. (mskcc.org)
  • Ibritumomab, like Rituximab, induces apoptosis in CD20+ B-cell lines in vitro. (centerwatch.com)
  • B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. (onmedica.com)
  • The partial response of RIT in solid tumors is primarily due to reduced accessibility of radio-probes to the cancer cells and their inferior radio-sensitivity. (army.mil)
  • The aim of this study was to evaluate whether cytotoxic T cells affect the response of established tumors and, above all, if they delay or prevent the development of distant metastases after RIT, using an immunocompetent syngeneic rat colon carcinoma model. (springeropen.com)
  • These findings motivated us to perform the present study to evaluate the effects of cytotoxic T cells on the response of established tumors and to establish whether they prevented the development of distant metastasis after RIT in our immunocompetent syngeneic rat colon carcinoma model. (springeropen.com)
  • Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. (nature.com)
  • CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. (nature.com)
  • Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors. (bioportfolio.com)
  • Multiple solid tumors have positive targets of mesothelin expressed on the surfaces of the tumor cells, we use the technique of CRISPR-Cas9 to knocked out the PD-1 and TCR of chimeric anti. (bioportfolio.com)
  • Cetuximab or control isotype-matched IgG1 was conjugated with the Cy5.5 fluorochrome and systemically injected into mice bearing human split thickness skin grafts, tumor cell line xenografts, transplanted human tumor xenografts, or mouse mesothelioma tumors. (aacrjournals.org)
  • The most common side effect associated with tositumomab treatment is lowered blood cell count. (cancerquest.org)
  • This phase I trial studies pretargeted radioimmunotherapy and donor peripheral blood stem cell transplant employing fludarabine phosphate and total-body irradiation (TBI) to treat patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. (clinicaltrials.gov)
  • STEM CELL INFUSION: Patients undergo autologous peripheral blood stem cell transplant (PBSCT) on day 0 per standard of care. (clinicaltrials.gov)
  • This is followed by an autologous stem cell transplant (using your own stem cells) to rescue the bone marrow after the high-dose chemotherapy. (medlineplus.gov)
  • Stem cell transplant is considered only as a final course of action. (mainlinehealth.org)
  • We found that radioimmunotherapy could kill HIV-infected cells both in blood samples that received antiretroviral treatment and within the central nervous system , demonstrating RIT offers real potential for being developed into an HIV cure. (medicalnewstoday.com)
  • CHICAGO - New York researchers have found that radioimmunotherapy (RIT) offers a strategy for curing human immunodeficiency virus (HIV) infection, according to a study highlighted on Tuesday at the RSNA 2013 meeting. (auntminnie.com)
  • Allogeneic hematopoietic cell transplantation (HCT) is a curative modality for patients with various malignant and nonmalignant hematopoietic diseases. (aacrjournals.org)
  • Frequency of Allogeneic Hematopoietic Cell Transplantation among High-or Intermediate-Risk AML Patients in First Complete Remission. (swedish.org)
  • We couldn't agree more with Dr. Press' comments about the importance of these results for patients with newly diagnosed follicular NHL as well as his views as to why this important therapeutic option is underutilized by physicians,' noted James Bianco, M.D., CEO of Cell Therapeutics. (medicalnewstoday.com)
  • High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model. (semanticscholar.org)
  • This Phase I/II radioimmunotherapy study was carried out to determine the maximum tolerated dose (MTD) and therapeutic potential of 131I-G250. (edu.au)
  • Radioimmunotherapy (RIT) is a rapidly emerging therapeutic modality for the treatment of a wide variety of cancers. (army.mil)
  • Another therapeutic agent already under investigation for various cancer types of all stages, called curcumin, is also known for inducing radio-sensitization/chemo-sensitization in cancer cells. (army.mil)
  • They found that this nano-curcumin formulation exhibits a higher therapeutic efficacy in cell proliferation and colony formation assays, and in a xenograft mouse model. (army.mil)
  • Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. (army.mil)
  • CD8-positive cells might play a crucial role in the therapeutic response to radiation, which has however not been investigated in radioimmunotherapy (RIT). (springeropen.com)
  • Fractionated radioimmunotherapy may improve therapeutic outcome by decreasing heterogeneity of the dose delivered to the tumor and by decreasing hematologic toxicity, thereby allowing an increased amount of radionuclide to be administered. (aacrjournals.org)
  • Although considered a feasible therapeutic option, the use of hematopoietic cell transplantation (HCT) remains controversial. (hindawi.com)
  • Cells affected by MCL proliferate in a nodular or diffuse pattern with two main cytologic variants, typical or blastic. (wikipedia.org)
  • The vast majority of patients with plasma cell neoplasms die of progressive disease despite high response rates to novel agents. (sigmaaldrich.com)
  • A new research project that could impact and expand the discovery of new treatment options for sickle cell patients has received significant federal funding. (news-medical.net)
  • Precision medicine in cancer treatment uses genetic changes in the cancer cells to select the best therapies for individual patients. (news-medical.net)
  • Thirty-three patients with measurable metastatic renal cell carcinoma were treated. (edu.au)
  • A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. (wikipedia.org)
  • Researchers found that splitting the dose over two or three fractions made it tolerable to patients while delivering higher radioactivity to tumor cells. (drugs.com)
  • Adult patients with documented B-cell NHL who failed at least one prior regimen of standard chemotherapy were eligible for this study. (drugs.com)
  • Going forward, Dadachova's team plans to investigate the ability of RIT to kill latently infected cells in patients who are not on ART. (auntminnie.com)
  • Patients with adequate autologous stem cell collection for transplantation (target ≥ 2.5 x 10^6 CD34+ cells/kg). (mayo.edu)
  • New technologies together with this new knowledge have given birth to the next generation of vaccines, adoptive cellular therapies and T cell modulating agents, all of which are being investigated in preclinical models and in patients. (keystonesymposia.org)
  • Hematopoietic stem cell transplantation is used to treat MM. However, most patients suffer relapse of disease, suggesting the pre-transplant regimens do not eliminate all cancerous cells. (fredhutch.org)
  • Of 13 patients with tumor cell CD22 expression determined by flow cytometry, seven of eight with strongly positive results had objective responses, versus one of five with negative or weakly positive results ( P = 0.032). (aacrjournals.org)
  • Establish an induced pluripotent stem cell (iPSC) bank for phenotypically well-characterized patients with NF1. (bioportfolio.com)
  • Brain metastases in non-small cell lung cancer (NSCLC) patients are more often detected due to imaging modalities improvements but also emerge because of improved treatments of the primary tumor which lead to a longer survival. (frontiersin.org)
  • Non-small cell lung cancer (NSCLC) is characterized by a high incidence of central nervous system (CNS) dissemination, with approximately 40% of patients developing brain metastases (BM) in the course of their disease ( 1 , 2 ) and leptomeningeal metastases (LM) appearance in a smaller percentage (3-5%) ( 3 ). (frontiersin.org)
  • Sinai Hospital patients receive radioimmunotherapy treatment intravenously as outpatients. (lifebridgehealth.org)
  • Radioimmunotherapy may affect some normal cells, causing lower red and white blood cell counts or bone marrow damage, which may make patients more susceptible to infection. (lifebridgehealth.org)
  • Patients are assessed for weeks after treatment, and growth factors may be prescribed to quickly raise white and red blood cell counts as needed. (lifebridgehealth.org)
  • Research will also be performed to find out which patients benefit most from these therapies and to see how these drug combinations precisely work together with GO to kill leukemia cells. (labome.org)
  • Using stem cells from blood, or bone marrow for transplant, we treat patients with a wide range of diseases. (mercy.com)
  • A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders. (swedish.org)
  • Finally, the article describes ongoing and planned trials of rituximab in other dosage schedules, in other B-cell neoplasms, and in conjunction with chemotherapy. (cancernetwork.com)
  • Giving rituximab together with combination chemotherapy may kill more cancer cells. (stanford.edu)
  • 2000) Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells treatment of relapsed/refractory neuroblastoma using an adenoviral vector. (springer.com)
  • The trial included 143 subjects with relapsed or refractory, low grade or follicular NHL or transformed B-cell NHL. (centerwatch.com)
  • Radioimmunotherapy with alpha-particle emitting radionuclides. (wikipedia.org)
  • Radioimmunotherapy (RIT) can be performed with various radionuclides. (ru.nl)
  • Purpose:The purpose of this studywas to analyze differentmechanisms (cell cycle synchronization, DNA damage, and apoptosis) that might underlie potential synergy between chemotherapy (paclitaxel or doxorubicin) and radioimmunotherapy with a radionuclides. (europa.eu)
  • However, β-emitting radionuclides are not optimal for killing the targeted hematopoietic cells due to their long path length and low dose rates ( 5 - 8 ). (aacrjournals.org)
  • Clearly, future studies will involve combining various traditional and targeted therapies in an effort to eliminate large tumor masses, metastatic disease, dormant cells, and antigen-negative variants. (aacrjournals.org)
  • Finally, we will discuss the potential of PAN-FUNGAL RIT the targeting of conserved fungal cell surface antigens by RIT as a treatment modality for fungi prior to the formal microbiological identification of the specific pathogen. (elsevier.com)
  • By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells. (wikipedia.org)
  • The cytotoxic T cells were depleted in 15 rats by anti-CD8 before the injection of the radioimmunoconjugate (400 MBq/kg body weight 177 Lu-BR96, which binds to the tumor-associated antigen Lewis Y). Fifteen other rats were treated with RIT only. (springeropen.com)
  • Conclusions: The La antigen represents a dead cancer cell-specific target in lung cancer, and DAB4 specifically targeted tumour tissue in vivo, particularly after chemotherapy. (edu.au)
  • B7-H3.BB.z-chimeric antigen receptor (CAR) T cells administered intracerebroventricularly or intratumorally mediate potent antitumor effects against cerebral ATRT xenografts in mice, with faster kinetics, greater potency and reduced systemic levels of inflammatory cytokines compared to CAR T cells administered intravenously. (nature.com)
  • following clearance of ATRT xenografts, B7-H3.BB.z-CAR T cells administered intracerebroventricularly or intravenously mediate antigen-specific protection from tumor rechallenge, both in the brain and periphery. (nature.com)
  • Fig. 4: B7-H3 CAR T cells persist in the brain and lead to antigen-specific protection from tumor rechallenge. (nature.com)
  • This may kill more tumor cells while causing fewer side effects to healthy tissue. (clinicaltrials.gov)
  • Radiation can be given directly to cancer cells and so less radiation goes to nearby normal tissue. (cancer.ca)
  • An abnormal increase in the number of cells in an organ or tissue. (learner.org)
  • Radiation oncologists use this type of treatment to destroy cancer cells and slow tumor growth without harming nearby healthy tissue. (cancer.net)
  • This helps target the tumor while avoiding healthy tissue near the cancer cells. (cancer.net)
  • All images show both granulation tissue ( filled arrowhead ) and tumor cell area ( arrowhead ). (springeropen.com)
  • White blood cells, called lymphocytes, are found in lymph tissue. (medlineplus.gov)
  • Necrosis is the death of most or all of the cells in an organ or tissue due to disease, injury, or failure of the blood supply. (omicsonline.org)
  • Necrosis is caused by external factors to the cell or tissue, such as infection, toxins, or trauma that result in the unregulated digestion of cell components. (omicsonline.org)
  • The results showed that RIT targeted and killed HAART-treated lymphocytes - types of white blood cells - and in most samples, reduced HIV infection to undetectable levels. (medicalnewstoday.com)
  • Fluid that carries lymphocytes, a type of white blood cells, through the body in a network of lymph vessels, which are like tiny veins. (mdanderson.org)
  • It occurs when a certain type of lymphocytes, or white blood cells, called B cells, begin to grow abnormally. (mainlinehealth.org)
  • Lymph contains white blood cells including a type of white blood cell called lymphocytes (such as B cells and T cells). (medicinenet.com)
  • In the normal life cycle of lymphocytes (a type of white blood cell), old lymphocytes die and the body creates new ones to replenish the supply. (medicinenet.com)
  • Within the hematopoietic system, L1 has been detected in cells of myelomonocytic and lymphoid origin such as lymphocytes and DCs ( 5 ). (rupress.org)
  • Neither the time to metastatic disease nor the fraction of animals developing disseminated disease was affected by cyclosporin A. This observation indicates that T cells might be involved in the response process of RIT in our model. (springeropen.com)
  • Using a catheter , these beads are placed inside the blood vessels that feed a tumour, delivering a high dose of radiation to the tumour and also blocking the supply of blood to the cancer cells. (cancer.ca)
  • The molecule attaches to cancer cells and delivers a high dose of radiation to the tumor. (healthcentral.com)
  • A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells. (learner.org)
  • It targets cancer cells remaining after the initial treatment. (cancer.net)
  • At high energy, protons can destroy cancer cells. (cancer.net)
  • One of the characteristics of cancer cells is that they grow and divide faster than normal cells. (encyclopedia.com)
  • Radiation also damages normal cells, but because normal cells are growing more slowly, they are better able to repair radiation damage than are cancer cells. (encyclopedia.com)
  • Recently, trials have begun to determine if there are ways to deliver radiation fractions so that they kill more cancer cells or have fewer side effects. (encyclopedia.com)
  • It uses a drug to focus on specific targets (molecules) in or on cancer cells. (medlineplus.gov)
  • Using these targets, the drug disables the cancer cells so they cannot spread. (medlineplus.gov)
  • Drugs used in chemotherapy, such as carmustine, etoposide phosphate, cytarabine, and melphalan (BEAM), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (mayo.edu)
  • A reaction occurs in the tumor when a beam of neutrons is sent into the tumor, destroying the cancer cells. (hopkinsmedicine.org)
  • This approach further limits the amount of non-specific toxicity to normal cells and allows for higher doses of radiation to cancer cells. (fredhutch.org)
  • When these "smart bullets" latch onto cancer cells, radiation starts working. (menstuff.org)
  • When they are delivered straight to the cancer cells, healthy tissues are spared while cancer cells are eliminated. (menstuff.org)
  • Medical isotopes are delivered to the cancer cells in several different ways. (menstuff.org)
  • If cancer is suspected, a biopsy may be performed to determine the existence of cancer cells. (mainlinehealth.org)
  • Cancer cells are in several portions of one or more organs and tissues. (mayoclinic.org)
  • RIT may be used because it does more harm to cancer cells since the radiation is delivered directly to the cells. (epnet.com)
  • It will take several months for cancer cells to die and the tumor to shrink. (epnet.com)
  • Drugs used in chemotherapy, such as prednisone, cyclophosphamide, doxorubicin, and vincristine, work in different ways to stop cancer cells from dividing so they stop growing or die. (stanford.edu)
  • Some block the ability of cancer cells to grow and spread. (stanford.edu)
  • Others find cancer cells and help kill them or carry cancer-killing substances to them. (stanford.edu)
  • Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. (stanford.edu)
  • Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. (biomedsearch.com)
  • Anti-CD45 Radioimmunotherapy Using 211 At with Bone Marrow Transplantation Prolongs Survival in a Disseminated Murine Leukemia Model. (swedish.org)
  • We evaluated the safety and effectiveness of radioimmunotherapy (RIT) using DAB4 radiolabeled with Lutetium-177 ( 177 Lu) in the murine Lewis Lung (LL2) carcinoma model, and determined whether combining RIT with DNA-damaging cisplatin-based chemotherapy, a PARP inhibitor (PARPi), or both alters treatment responses. (edu.au)
  • We here propose a 3D alginate-based hydrogel as extracellular microenvironment to evaluate the effects of the three-dimensionality on biological and immunological properties of NB cells. (frontiersin.org)
  • The signaling enzyme phospholipase D (PLD) and the lipid second messenger it generates, phosphatidic acid (PA), are implicated in many cell biological processes, including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. (biomedsearch.com)
  • Oliver W. Press, M.D., Ph.D., Member of the Fred Hutchinson Cancer Research Center and Professor at the University of Washington, commented in his editorial that the studies 'confirm and extend prior data demonstrating the tremendous potential of RIT in the treatment of B-cell NHL at diagnosis and after relapse at both conventional and myeloablative doses. (medicalnewstoday.com)
  • The study identified cell cycle kinase inhibitors as promising partners for combination treatment of aggressive DLBCL with Betalutin®, warranting further exploration in preclinical models. (prnewswire.co.uk)
  • AG-014699) was combined with chemotherapy and the effects of combined treatment on tumour growth, tumour cell DNA damage and death, and intratumoural DAB4 binding were also analysed. (edu.au)
  • Representative example demonstrating activation and expansion of γδ T cells during pamidronate/IL-2 treatment. (bloodjournal.org)
  • In vivo results represent percentage of increase according to the following calculation: (Vy9δ2 T-cell number on day 8 after pamidronate/IL-2 infusion)−(Vγ9δ2 T-cell number before treatment)/(Vγ9δ2 T-cell number before treatment) × 100. (bloodjournal.org)
  • This form of treatment is termed radioimmunotherapy. (cancerquest.org)
  • To this goal, we generated conditional knockout mice in which L1 expression was ablated in the hematopoietic precursors as well as in endothelial cells (ECs). (rupress.org)
  • Cells that look abnormal under a microscope but are not cancerous. (learner.org)
  • These abnormal blood cells, or cancerous cells, prevent your blood from performing many of its functions. (mercy.com)
  • The complete response rate was determined by both conventional CT and the use of PET, or positron emission tomographya scan that measures abnormal molecular cell activity. (upmc.com)
  • Fig. 2: Locoregional administration of B7-H3 CAR T cells is more potent and results in lower systemic inflammatory cytokine levels than IV administration against aggressive orthotopic ATRT xenografts. (nature.com)
  • Fig. 3: Locoregionally administered B7-H3 CAR T cells home more rapidly to cerebral ATRT xenografts than those administered intravenously. (nature.com)
  • Furthermore, CD38 has not been explored as a RIT target despite its uniform high expression on malignant plasma cells. (sigmaaldrich.com)
  • A defining characteristic of MCL is mutation and overexpression of cyclin D1, a cell cycle gene, that contributes to the abnormal proliferation of the malignant cells. (wikipedia.org)
  • For this reason, both the peripheral blood and bone marrow are evaluated for the presence of malignant cells. (wikipedia.org)
  • In this manner, cytotoxic radiation is delivered directly to malignant cells. (centerwatch.com)
  • Results underscore promise of radioimmunotherapy in ASCT and warra. (bio-medicine.org)
  • The initial depletion of CD8-positive cells in our syngeneic rat colon carcinoma model resulted in a higher frequency of animals developing metastases. (springeropen.com)
  • Nordic Nanovector ASA (OSE: NANO) notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapies were made at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition ( 1-4 December 2018 in San Diego, CA , USA). (prnewswire.co.uk)